<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAH</journal-id>
<journal-id journal-id-type="hwp">sptah</journal-id>
<journal-title>Therapeutic Advances in Hematology</journal-title>
<issn pub-type="ppub">2040-6207</issn>
<issn pub-type="epub">2040-6215</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2040620713485375</article-id>
<article-id pub-id-type="publisher-id">10.1177_2040620713485375</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inherited predisposition to multiple myeloma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Koura</surname><given-names>Divya T.</given-names></name>
<aff id="aff1-2040620713485375">The Winship Cancer Institute of Emory University, Atlanta, GA, USA</aff>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Langston</surname><given-names>Amelia A.</given-names></name>
<aff id="aff2-2040620713485375">The Winship Cancer Institute of Emory University, 1365 Clifton Rd NE, Building C-4006, Atlanta, GA 30322, USA</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-2040620713485375"><email>alangst@emory.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>291</fpage>
<lpage>297</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, after non-Hodgkin lymphoma. Family pedigree analyses of high-risk families, case-control studies and racial disparities in disease incidence all point to a potential inherited predisposition to MM. Genome-wide association studies (GWASs) have identified susceptibility loci in a number of cancers and such studies are currently underway in MM. To date, GWASs in MM have identified several potential regions of interest for further study on chromosomes 3p22, 7p15.3, 8q24 and 2p23.3. In addition, several targets of paraproteins (so called ‘paratargs’) in MM have been identified. Hyperphosphorylation of the paratarg protein, which is inherited in an autosomal dominant manner, appears a common mechanism underlying the antigenicity of these proteins. One particular protein, hyperphosphorylated paratarg-7 (pP-7) is a common target in persons with myeloma and has also been identified in affected members of several high-risk MM families. It appears that the frequency of pP-7 as an antigenic target may be particularly high in African American patients with MM, which could be part of the explanation for observed racial disparities in the incidence of MM. In this review we focus on available data in the area of inherited predisposition to MM, and highlight future research directions.</p>
</abstract>
<kwd-group>
<kwd>autoantigens/genetics</kwd>
<kwd>genetic predisposition to disease</kwd>
<kwd>monoclonal gammopathy of undetermined significance/genetics</kwd>
<kwd>multiple myeloma/epidemiology</kwd>
<kwd>multiple myeloma/genetics</kwd>
<kwd>paraproteins/genetics</kwd>
<kwd>phosphorylation/physiology</kwd>
<kwd>risk factors</kwd>
<kwd>Waldenström macroglobulinemia/genetics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2040620713485375" sec-type="intro">
<title>Introduction</title>
<p>Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 0.8% of cancer cases worldwide and comprises about 13% of hematologic malignancies [<xref ref-type="bibr" rid="bibr18-2040620713485375">Ferlay <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr32-2040620713485375">Kyle and Rajkumar, 2004</xref>]. The disease is characterized by infiltration of the bone marrow, bones and sometimes other tissues by malignant plasma cells, which typically produce a monoclonal paraprotein. Common clinical manifestations include lytic bony lesions, renal impairment, anemia, hypercalcemia and immune dysfunction. MM may be preceded by a monoclonal gammopathy of undetermined significance (MGUS), which is present in about 3% of the general population over the age of 50 years, and carries a risk of progression to MM of about 1% per year [<xref ref-type="bibr" rid="bibr33-2040620713485375">Kyle <italic>et al.</italic> 2006</xref>].</p>
<p>Surveillance Epidemiology and End Results (SEER) data indicate that, in the United States, the median age at diagnosis of MM is 69 years, with an age-adjusted incidence of 5.8 cases per 100,000 persons per year. About 75% of MM cases are diagnosed in persons over 50 years of age. It is estimated that in 2012, 21,700 people will be diagnosed and 10,710 people will die of MM in the US.</p>
<p>The incidence of MM varies widely, ranging from 0.4 to 5 cases per 100,000 persons, with the highest rates in Australia, New Zealand, North America and parts of Europe, and the lowest rates in Asia [<xref ref-type="bibr" rid="bibr46-2040620713485375">Parkin <italic>et al.</italic> 2005</xref>]. Striking racial differences in MM have long been noted, with the incidence in the black population being approximately twice that of the white population in the US. Alternatively, the risk of MM is very low in individuals of Asian descent [<xref ref-type="bibr" rid="bibr27-2040620713485375">Howlader <italic>et al.</italic> 2012</xref>].</p>
<p>While the causes of MM remain poorly understood, factors affecting risk for development of the disease include age, gender, racial and ethnic background, underlying immunodeficiency, exposure to radiation, exposure to dioxin-related compounds, and family history of MM and other hematolymphoid neoplasms [<xref ref-type="bibr" rid="bibr1-2040620713485375">Alexander <italic>et al.</italic> 2007</xref>]. Several lines of direct and indirect evidence also suggest the existence of inherited factors, which may predispose individuals to development of MM, MGUS and other related cancers. Here we focus on available data in this area and highlight future research directions.</p>
</sec>
<sec id="section2-2040620713485375">
<title>Myeloma in families</title>
<p>The idea of a potential familial predisposition to MM was first advanced in the 1920s. In 1925, Meyerding highlighted 13 cases of MM; in his series, one patient with myeloma had an aunt with a bone disease with a fractured leg [<xref ref-type="bibr" rid="bibr42-2040620713485375">Meyerding, 1925</xref>]. In a review of MM published in 1928, Geshickter and Copeland briefly mention a case in which two siblings both died of myeloma [<xref ref-type="bibr" rid="bibr19-2040620713485375">Geschickter and Copeland, 1928</xref>]. In 1954, the first detailed case report of two sisters with proven MM was published by Mandema and Wildervanck [<xref ref-type="bibr" rid="bibr38-2040620713485375">Mandema and Wildervanck, 1954</xref>]. By 1965, there were at least 10 published reports of families with 2 or more affected members [<xref ref-type="bibr" rid="bibr2-2040620713485375">Alexander and Benninghoff, 1965</xref>] and families with many combinations of affected members were described. More recently, one report described 39 families with multiple members affected by MM and related disorders (MGUS, Waldenström macroglobulinemia [WM], amyloidosis or cryoglobulinemia) [<xref ref-type="bibr" rid="bibr36-2040620713485375">Lynch <italic>et al.</italic> 2005</xref>], and another detailed 8 African American families with multiple cases of MM or MGUS [<xref ref-type="bibr" rid="bibr29-2040620713485375">Jain <italic>et al.</italic> 2009</xref>]. The patterns of cases in these families do not follow a simple Mendelian pattern, suggesting a more complex genetic basis for the phenotype. A curious aspect of the latter two reports is the observation of anticipation, which is the occurrence of disease at an earlier age in later generations. This type of inheritance has been most closely associated with disorders involving trinucleotide repeat errors such as Fragile X syndrome and muscular dystrophies [<xref ref-type="bibr" rid="bibr43-2040620713485375">Monckton and Caskey, 1995</xref>]. Nevertheless, it is important to remember that with cancer phenotypes there may be an element of ascertainment bias related to heightened awareness of the disease, so the observation of anticipation should be interpreted with caution. To date, over 100 families with multiple affected members with myeloma or other plasma cell dyscrasias have been described and these provide strong evidence for the existence of inherited risk factors for MM.</p>
<p>There are a few hints that the risk of MM may also be modestly increased in association with several more well-defined cancer family syndromes. An excess of MM has been noted among first-degree relatives of Ashkenazi Jewish carriers of common <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations [<xref ref-type="bibr" rid="bibr54-2040620713485375">Struewing <italic>et al.</italic> 1997</xref>]. Sobol and colleagues later described a family with multiple cases of MM in which two of the affected members also developed breast cancer. Genotyping of one of these doubly affected women revealed a nonsense mutation in the <italic>BRCA2</italic> gene [<xref ref-type="bibr" rid="bibr53-2040620713485375">Sobol <italic>et al.</italic> 2002</xref>]. Finally, Dilworth and colleagues described a melanoma-prone family in which a germline mutation in <italic>CDKN2A</italic> (p16) was found in a family member with MM; they went on to demonstrate loss of the normal allele in the malignant plasma cells, suggesting a pathogenic role in tumor development [<xref ref-type="bibr" rid="bibr15-2040620713485375">Dilworth <italic>et al.</italic> 2000</xref>]. While these observations are circumstantial, they support the notion that susceptibility to MM can occur though general mechanisms common to a number of seemingly unrelated tumor types.</p>
</sec>
<sec id="section3-2040620713485375">
<title>Case-control and cohort studies</title>
<p>Case-control studies also support the existence of inherited risk factors for the development of MM and point to an association with other hematolymphoid malignancies. Bourguet and colleagues performed a hospital-based case-control study to assess whether people with a family history of cancers including MM were at increased risk of developing MM [<xref ref-type="bibr" rid="bibr7-2040620713485375">Bourguet <italic>et al.</italic> 1985</xref>]. They looked at 439 cases of MM seen at Duke University Medical Center between 1967 and 1982 as well as 1317 matched controls. Of these groups, three cases and four controls had a family member with MM. In this analysis, individuals with a family history of cancer of any type had a relative risk for MM of 1.4 (95% confidence interval [CI] 0.5–10.1), and those with a family history of MM had a relative risk of 2.4 (95% CI 1.1–1.8). Another population-based case-control study in Sweden examined 229 cases with myeloma and 220 controls [<xref ref-type="bibr" rid="bibr17-2040620713485375">Eriksson and Hallberg, 1992</xref>]. They found an increased risk for myeloma among persons with first-degree relatives with hematologic malignancies (relative risk [RR] 2.36, 90% CI 0.9–6.15) and MM (RR 5.64, 90% CI 1.16–27.51). In addition, other malignancies were examined, and persons with first-degree relatives with prostate cancer and brain tumors had an increased risk for MM, with RR 3.11 (90% CI 1.25–7.71) and 6.61 (90% CI 1.42–30.67), respectively.</p>
<p>Given the higher incidence of MM in blacks than whites, Brown and colleagues separated black and white patients with myeloma in a population-based case-control study that included 361 white persons and 204 black persons with myeloma [<xref ref-type="bibr" rid="bibr9-2040620713485375">Brown <italic>et al.</italic> 1999</xref>]. They observed an increased risk of MM among individuals with a family history of any hematolymphoid cancer, with an odds ratio (OR) of 1.7 (95% CI 1.0–2.8). The highest risk of MM was seen in persons with a family history of MM in a first-degree relative, which was associated with an OR of 3.7 (95% CI 1.2–12). In their study, the OR for myeloma was 17.4 (95% CI 2.4–348) among black individuals with a first-degree relative with MM and 1.5 (95% CI 0.3–6.4) for white individuals with similar family history. Significant associations with other nonhematologic cancer types were not observed in this study.</p>
<p>The largest case-control study focused on myeloma included 13,896 Swedish MM patients and 54,365 matched controls, and assessed rates of hematologic malignancies, MGUS and solid tumors in first-degree relatives [<xref ref-type="bibr" rid="bibr31-2040620713485375">Kristinsson <italic>et al.</italic> 2009</xref>]. First-degree relatives of people with MM had a higher risk of developing MM (RR 2.1, 95% CI 1.6–2.9), MGUS (RR 2.1; CI 1.5–3.1), ALL (RR 2.1, CI 1.0–4.2) and any solid tumor (RR 1.1, CI 1.0–1.1).</p>
</sec>
<sec id="section4-2040620713485375">
<title>HLA associations with myeloma</title>
<p>A number of studies have evaluated the possible association of MM with certain human leukocyte antigen (HLA) types. Mason and Cullen evaluated 63 myeloma patients in comparison with 83 healthy controls, and noted an increased frequency of HLA-A5 in patients with myeloma [<xref ref-type="bibr" rid="bibr40-2040620713485375">Mason and Cullen, 1975</xref>]. In 1983, Leech and colleagues looked specifically at black myeloma patients in Louisiana, and used a control group of 138 normal healthy black males from the same area. They saw no significant relationship between HLA-A or HLA-B serotypes and myeloma; however, HLA-Cw5 was seen in a higher proportion of myeloma patients than healthy controls (RR 15) [<xref ref-type="bibr" rid="bibr34-2040620713485375">Leech <italic>et al.</italic> 1982</xref>]. Interpretation of these early observations is limited by the crude state of characterization of the HLA loci at the time of the studies, as well as small sample sizes of patient and control groups. Subsequent studies have continued to show varying results, including possible associations with HLA-Cw2 [<xref ref-type="bibr" rid="bibr49-2040620713485375">Pottern <italic>et al.</italic> 1992</xref>] and HLA-B18 [<xref ref-type="bibr" rid="bibr47-2040620713485375">Patel <italic>et al.</italic> 2002</xref>]. Taken together, it is difficult at this point to draw firm conclusions regarding associations with particular HLA antigens or haplotypes, but this is an area of active investigation in the era of sequence-based HLA typing techniques.</p>
</sec>
<sec id="section5-2040620713485375">
<title>Hyperphosphorylated ‘paratargs’ and myeloma risk</title>
<p>In 2009, Preuss and Grass used a modified SEREX (Serological Identification of Recombinantly Expressed Clones) approach to screen a human fetal brain derived protein macroarray with the sera of 192 patients with immunoglobulin G (IgG) or immunoglobulin A (IgA) MM or MGUS, and found that 29 of 192 paraproteins (15.1%) reacted with a single target protein which they called paraprotein target 7, or paratarg-7 [<xref ref-type="bibr" rid="bibr50-2040620713485375">Preuss <italic>et al.</italic> 2009</xref>]. Sequence analysis demonstrated that paratarg-7 is a ubiquitously expressed protein also known as STOML2, and its natural function remains unclear. The same group went on to demonstrate that, while the DNA sequence of paratarg-7 in patients and healthy controls is identical, patients with a paratarg-7-directed paraprotein carry a hyperphosphorylated form of the paratarg-7 protein (pP-7) [<xref ref-type="bibr" rid="bibr21-2040620713485375">Grass <italic>et al.</italic> 2009</xref>]. This analysis has now been extended to include patients with WM and immunoglobulin M (IgM) MGUS, and 11% of these patients demonstrated paraproteins directed toward pP-7 [<xref ref-type="bibr" rid="bibr24-2040620713485375">Grass <italic>et al.</italic> 2011d</xref>]. It is not yet clear whether the clinical features of patients with pP-7 specific paraproteins are different from those of other patients. Taken together, these studies suggest that pP-7 may represent a unique antigenic target, with a propensity to generate immune responses that eventually lead to malignant transformation of plasma cells.</p>
<p>Examination of family members of MM/MGUS patients with anti-paratarg-7 paraproteins has demonstrated that pP-7 is inherited in an autosomal dominant manner [<xref ref-type="bibr" rid="bibr21-2040620713485375">Grass <italic>et al.</italic> 2009</xref>]. In a recent study of four families with familial MM/MGUS, paraproteins from affected members of two of the families were found to target pP-7. Paraproteins from four affected members of a third family targeted a different phosphorylated protein, termed pP-8, which is encoded by the <italic>ATG13</italic> gene and is also inherited in its hyperphosphorylated form in an autosomal dominant fashion [<xref ref-type="bibr" rid="bibr22-2040620713485375">Grass <italic>et al.</italic> 2011b</xref>]. Other autoantigenic paraprotein targets (paratargs 2, 5, 6, 7, 8, 9, 10 and 11) have also been identified in small numbers of patients and in each case the proteins are hyperphosphorylated in affected patients. These data support the hypothesis that hyperphosphorylation of selected proteins may be a common mechanism leading to development of autoreactive plasma cell clones [<xref ref-type="bibr" rid="bibr23-2040620713485375">Grass <italic>et al.</italic> 2011c</xref>]. Recent data from the same group suggest that the hyperphosphorylated state of these antigenic targets is a result of alterations in genes/proteins in the phosphorylation/dephosphorylation machinery upstream of phosphatase 2A [<xref ref-type="bibr" rid="bibr51-2040620713485375">Preuss <italic>et al.</italic> 2011</xref>] and linkage analysis implicates a locus on chromosome 4q35 [<xref ref-type="bibr" rid="bibr23-2040620713485375">Grass <italic>et al.</italic> 2011c</xref>].</p>
<p>Initial studies on paratarg-7, which were performed in German MM and MGUS patients, demonstrated the presence of pP-7 (and a pP-7-directed paraprotein) in 13.9% of a series of 252 consecutive patients and 2% of population controls; the relative risk for pP-7 carriers developing MM/MGUS was 7.9 [<xref ref-type="bibr" rid="bibr21-2040620713485375">Grass <italic>et al.</italic> 2009</xref>]. In a study of Japanese patients and controls, the prevalence of pP-7 was 4.5% among patients and 0.36% among controls, and the relative risk of pP-7 carriers developing MM/MGUS was 13.1 [<xref ref-type="bibr" rid="bibr20-2040620713485375">Grass <italic>et al.</italic> 2011a</xref>]. The highest prevalence of pP-7 has been observed among African American MM/MGUS patients, where 28% of patients were noted to carry the hyperphosphorylated form of the protein [<xref ref-type="bibr" rid="bibr23-2040620713485375">Grass <italic>et al.</italic> 2011c</xref>]. While much more population-based work is needed, it appears that differential frequencies of pP-7 (and possibly other hyperphosphorylated proteins) in distinct populations may account for some of the observed difference in the incidence of MM and associated disorders across different ethnic and geographic groups.</p>
</sec>
<sec id="section6-2040620713485375">
<title>Genome-wide association studies</title>
<p>In the 1980s and 1990s, a number of cancer susceptibility genes were identified through linkage analysis in high-risk families. Mutations in these genes, which are associated with breast and ovarian cancer (<italic>BRCA1</italic> and <italic>BRCA2</italic>) [<xref ref-type="bibr" rid="bibr26-2040620713485375">Hall <italic>et al.</italic> 1990</xref>; <xref ref-type="bibr" rid="bibr57-2040620713485375">Wooster <italic>et al.</italic> 1994</xref>], colorectal cancer (<italic>APC</italic> and mismatch repair genes <italic>MLH1</italic> and <italic>MSH2</italic>) [<xref ref-type="bibr" rid="bibr6-2040620713485375">Bodmer <italic>et al.</italic> 1987</xref>; <xref ref-type="bibr" rid="bibr35-2040620713485375">Lindblom <italic>et al.</italic> 1993</xref>; <xref ref-type="bibr" rid="bibr48-2040620713485375">Peltomaki <italic>et al.</italic> 1993</xref>] and melanoma (<italic>CKDN2A</italic>) [<xref ref-type="bibr" rid="bibr11-2040620713485375">Cannon-Albright <italic>et al.</italic> 1992</xref>] produce highly penetrant phenotypes, but mutations are rare and account for the minority of ‘familial’ cancers. Statistical and epidemiological studies suggest that most of the inherited susceptibility to common cancers is likely to result from inheritance of multiple genetic variants, each of which has a small to moderate effect. This model of inheritance requires study of much larger numbers of cases and necessitates use of alternative methods of genetic analysis.</p>
<p>Over the past decade, genome-wide association studies (GWASs) have emerged as a powerful tool for large-scale genetic studies, as this approach allows the entire genome to be efficiently interrogated through analysis of single nucleotide polymorphisms (SNPs) in large populations of affected and unaffected individuals. Furthermore, the method complements earlier approaches that target specific candidate genes. To date, GWASs have localized over 150 candidate regions harboring potential susceptibility loci for a variety of different cancer types [<xref ref-type="bibr" rid="bibr3-2040620713485375">Amos <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr5-2040620713485375">Amundadottir <italic>et al.</italic> 2006</xref>, <xref ref-type="bibr" rid="bibr4-2040620713485375">2009</xref>; <xref ref-type="bibr" rid="bibr13-2040620713485375">Crowther-Swanepoel <italic>et al.</italic> 2010</xref>; <xref ref-type="bibr" rid="bibr14-2040620713485375">Di Bernardo <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr16-2040620713485375">Eeles <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr25-2040620713485375">Gudmundsson <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr30-2040620713485375">Kiemeney <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr41-2040620713485375">McKay <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr45-2040620713485375">Papaemmanuil <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr52-2040620713485375">Shete <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr55-2040620713485375">Trevino <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr56-2040620713485375">Wang <italic>et al.</italic> 2008</xref>; <xref ref-type="bibr" rid="bibr58-2040620713485375">Wrensch <italic>et al.</italic> 2009</xref>; <xref ref-type="bibr" rid="bibr59-2040620713485375">Wu <italic>et al.</italic> 2009</xref>]. Notably, at least seven distinct regions have been associated with multiple different tumor types, suggesting related or common mechanisms underlying predisposition.</p>
<p>The one published GWAS in MM has produced interesting preliminary results. Broderick and colleagues conducted a GWAS using MM cases and controls from separate cohorts in the UK and Germany [<xref ref-type="bibr" rid="bibr8-2040620713485375">Broderick <italic>et al.</italic> 2012</xref>]. Their analysis identified two genomic regions that were significantly associated with MM at 3p22 and 7p15.3, as well as a third region at 2p23.3, which had a weaker association. Subsequently, Martina and colleagues genotyped SNPs of interest within these three regions in an additional 1139 MM cases and 1352 controls, and validated the associations in their own study population [<xref ref-type="bibr" rid="bibr39-2040620713485375">Martino <italic>et al.</italic> 2012</xref>]. Current studies are aimed at more detailed analysis of the regions of interest in order to identify the causative polymorphisms. Interestingly, the 7p15.3 region contains a gene, <italic>CDCA7L</italic>, which is a MYC interacting gene [<xref ref-type="bibr" rid="bibr28-2040620713485375">Huang <italic>et al.</italic> 2005</xref>; <xref ref-type="bibr" rid="bibr37-2040620713485375">Maertens <italic>et al.</italic> 2006</xref>], making it a logical candidate gene for further analysis.</p>
<p>Another study examined genetic variation in the 8q24 region in MM, based on previous GWASs that have demonstrated associations of this general region with risk of glioma, chronic lymphocytic leukemia (CLL), and breast, prostate, bladder, colorectal and ovarian cancer [<xref ref-type="bibr" rid="bibr12-2040620713485375">Chung and Chanock, 2011</xref>]. In this study, Campa and colleagues genotyped 20 SNPs within the 8q24 region in 1188 MM cases and 2465 controls, and confirmed an association of a SNP within this region with MM [<xref ref-type="bibr" rid="bibr10-2040620713485375">Campa <italic>et al.</italic> 2012</xref>]. Interestingly, this particular SNP has also been specifically associated with CLL, suggesting the possibility of a common susceptibility locus in related B-lineage malignancies [<xref ref-type="bibr" rid="bibr13-2040620713485375">Crowther-Swanepoel <italic>et al.</italic> 2010</xref>].</p>
<p>GWASs have inherent drawbacks, especially in relatively rare diseases such as MM, where the increase in risk is small or modest. Without large numbers of both cases and controls, studies may lack statistical power to identify weaker (less penetrant) associations. Furthermore, large numbers of SNPs must be evaluated to avoid missing important associations. False-negative and false-positive associations may also reflect case and control population selection, particularly in light of the varying rates of disease and allele frequencies in different ethnic groups. In order to overcome these limitations, groups are forming consortia to pool patients and controls for larger scale genetic studies. Examples include the MyelomA Genetics International Consortium (MAGIC) and the International Multiple Myeloma rESEarch (IMMEnSE) consortium [<xref ref-type="bibr" rid="bibr39-2040620713485375">Martino <italic>et al.</italic> 2012</xref>; <xref ref-type="bibr" rid="bibr44-2040620713485375">Morgan <italic>et al.</italic> 2012</xref>].</p>
</sec>
<sec id="section7-2040620713485375" sec-type="conclusions">
<title>Conclusion and future directions</title>
<p>Several lines of evidence point to a genetic predisposition to MM and other plasma cell dyscrasias. Until recent years, only case-control studies and reports of occasional high risk families supported this view. More recently, identification of hyperphosphorylated paratarg proteins and identification of putative susceptibility loci by GWASs have provided more firm evidence indicating inherited predisposition to MM and related disorders. The discovery of pP-7 as a frequent target of paraproteins in MM offers a potential link between the old concept of chronic antigenic stimulation as a potential cause of MM, and observations of familial predisposition as well as racial disparities in the incidence of MM. GWASs have to date identified several susceptibility potential regions of interest in MM and further molecular studies aimed at identification of specific genes of interest are ongoing. Although these discoveries are provocative, further work will be required to identify the genes and mechanisms underlying inherited susceptibility to MM, and these studies will be facilitated by the use of additional resources such as family registries and large-scale consortia.</p>
</sec>
</body>
<back>
<ack>
<p>We would like to thank Leon Bernal-Mizrachi, Sagar Lonial, Ajay Nooka and Lawrence Boise for their helpful discussions regarding this manuscript.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest in preparing this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>D.</given-names></name>
<name><surname>Mink</surname><given-names>P.</given-names></name>
<name><surname>Adami</surname><given-names>H.</given-names></name>
<name><surname>Cole</surname><given-names>P.</given-names></name>
<name><surname>Mandel</surname><given-names>J.</given-names></name>
<name><surname>Oken</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Multiple myeloma: a review of the epidemiologic literature</article-title>. <source>Int J Cancer</source> <volume>120</volume>(<supplement>Suppl 12</supplement>): <fpage>40</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr2-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>L.</given-names></name>
<name><surname>Benninghoff</surname><given-names>D.</given-names></name>
</person-group> (<year>1965</year>) <article-title>Familial multiple myeloma</article-title>. <source>J Natl Med Assoc</source> <volume>57</volume>: <fpage>471</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr3-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amos</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Broderick</surname><given-names>P.</given-names></name>
<name><surname>Gorlov</surname><given-names>I.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Eisen</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>616</fpage>–<lpage>622</lpage>.</citation>
</ref>
<ref id="bibr4-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amundadottir</surname><given-names>L.</given-names></name>
<name><surname>Kraft</surname><given-names>P.</given-names></name>
<name><surname>Stolzenberg-Solomon</surname><given-names>R.</given-names></name>
<name><surname>Fuchs</surname><given-names>C.</given-names></name>
<name><surname>Petersen</surname><given-names>G.</given-names></name>
<name><surname>Arslan</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>986</fpage>–<lpage>990</lpage>.</citation>
</ref>
<ref id="bibr5-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amundadottir</surname><given-names>L.</given-names></name>
<name><surname>Sulem</surname><given-names>P.</given-names></name>
<name><surname>Gudmundsson</surname><given-names>J.</given-names></name>
<name><surname>Helgason</surname><given-names>A.</given-names></name>
<name><surname>Baker</surname><given-names>A.</given-names></name>
<name><surname>Agnarsson</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>A common variant associated with prostate cancer in European and African populations</article-title>. <source>Nat Genet</source> <volume>38</volume>: <fpage>652</fpage>–<lpage>658</lpage>.</citation>
</ref>
<ref id="bibr6-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bodmer</surname><given-names>W.</given-names></name>
<name><surname>Bailey</surname><given-names>C.</given-names></name>
<name><surname>Bodmer</surname><given-names>J.</given-names></name>
<name><surname>Bussey</surname><given-names>H.</given-names></name>
<name><surname>Ellis</surname><given-names>A.</given-names></name>
<name><surname>Gorman</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>1987</year>) <article-title>Localization of the gene for familial adenomatous polyposis on chromosome 5</article-title>. <source>Nature</source> <volume>328</volume>: <fpage>614</fpage>–<lpage>616</lpage>.</citation>
</ref>
<ref id="bibr7-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourguet</surname><given-names>C.</given-names></name>
<name><surname>Grufferman</surname><given-names>S.</given-names></name>
<name><surname>Delzell</surname><given-names>E.</given-names></name>
<name><surname>DeLong</surname><given-names>E.</given-names></name>
<name><surname>Cohen</surname><given-names>H.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Multiple myeloma and family history of cancer. A case-control study</article-title>. <source>Cancer</source> <volume>56</volume>: <fpage>2133</fpage>–<lpage>2139</lpage>.</citation>
</ref>
<ref id="bibr8-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broderick</surname><given-names>P.</given-names></name>
<name><surname>Chubb</surname><given-names>D.</given-names></name>
<name><surname>Johnson</surname><given-names>D.</given-names></name>
<name><surname>Weinhold</surname><given-names>N.</given-names></name>
<name><surname>Forsti</surname><given-names>A.</given-names></name>
<name><surname>Lloyd</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk</article-title>. <source>Nat Genet</source> <volume>44</volume>: <fpage>58</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr9-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>L.</given-names></name>
<name><surname>Linet</surname><given-names>M.</given-names></name>
<name><surname>Greenberg</surname><given-names>R.</given-names></name>
<name><surname>Silverman</surname><given-names>D.</given-names></name>
<name><surname>Hayes</surname><given-names>R.</given-names></name>
<name><surname>Swanson</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Multiple myeloma and family history of cancer among blacks and whites in the U.S</article-title>. <source>Cancer</source> <volume>85</volume>: <fpage>2385</fpage>–<lpage>2390</lpage>.</citation>
</ref>
<ref id="bibr10-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campa</surname><given-names>D.</given-names></name>
<name><surname>Martino</surname><given-names>A.</given-names></name>
<name><surname>Sainz</surname><given-names>J.</given-names></name>
<name><surname>Buda</surname><given-names>G.</given-names></name>
<name><surname>Jamroziak</surname><given-names>K.</given-names></name>
<name><surname>Weinhold</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium</article-title>. <source>Br J Haematol</source> <volume>157</volume>: <fpage>331</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr11-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cannon-Albright</surname><given-names>L.</given-names></name>
<name><surname>Goldgar</surname><given-names>D.</given-names></name>
<name><surname>Meyer</surname><given-names>L.</given-names></name>
<name><surname>Lewis</surname><given-names>C.</given-names></name>
<name><surname>Anderson</surname><given-names>D.</given-names></name>
<name><surname>Fountain</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22</article-title>. <source>Science</source> <volume>258</volume>: <fpage>1148</fpage>–<lpage>1152</lpage>.</citation>
</ref>
<ref id="bibr12-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chung</surname><given-names>C.</given-names></name>
<name><surname>Chanock</surname><given-names>S.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Current status of genome-wide association studies in cancer</article-title>. <source>Hum Genet</source> <volume>130</volume>: <fpage>59</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr13-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crowther-Swanepoel</surname><given-names>D.</given-names></name>
<name><surname>Broderick</surname><given-names>P.</given-names></name>
<name><surname>Di Bernardo</surname><given-names>M.</given-names></name>
<name><surname>Dobbins</surname><given-names>S.</given-names></name>
<name><surname>Torres</surname><given-names>M.</given-names></name>
<name><surname>Mansouri</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk</article-title>. <source>Nat Genet</source> <volume>42</volume>: <fpage>132</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr14-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Bernardo</surname><given-names>M.</given-names></name>
<name><surname>Crowther-Swanepoel</surname><given-names>D.</given-names></name>
<name><surname>Broderick</surname><given-names>P.</given-names></name>
<name><surname>Webb</surname><given-names>E.</given-names></name>
<name><surname>Sellick</surname><given-names>G.</given-names></name>
<name><surname>Wild</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>1204</fpage>–<lpage>1210</lpage>.</citation>
</ref>
<ref id="bibr15-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dilworth</surname><given-names>D.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Stewart</surname><given-names>A.</given-names></name>
<name><surname>Berenson</surname><given-names>J.</given-names></name>
<name><surname>Lassam</surname><given-names>N.</given-names></name>
<name><surname>Hogg</surname><given-names>D.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Germline CDKN2A mutation implicated in predisposition to multiple myeloma</article-title>. <source>Blood</source> <volume>95</volume>: <fpage>1869</fpage>–<lpage>1871</lpage>.</citation>
</ref>
<ref id="bibr16-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eeles</surname><given-names>R.</given-names></name>
<name><surname>Kote-Jarai</surname><given-names>Z.</given-names></name>
<name><surname>Giles</surname><given-names>G.</given-names></name>
<name><surname>Olama</surname><given-names>A.</given-names></name>
<name><surname>Guy</surname><given-names>M.</given-names></name>
<name><surname>Jugurnauth</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Multiple newly identified loci associated with prostate cancer susceptibility</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>316</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr17-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eriksson</surname><given-names>M.</given-names></name>
<name><surname>Hallberg</surname><given-names>B.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study</article-title>. <source>Cancer Causes Control</source> <volume>3</volume>: <fpage>63</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr18-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Shin</surname><given-names>H.</given-names></name>
<name><surname>Bray</surname><given-names>F.</given-names></name>
<name><surname>Forman</surname><given-names>D.</given-names></name>
<name><surname>Mathers</surname><given-names>C.</given-names></name>
<name><surname>Parkin</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title>. <source>Int J Cancer</source> <volume>127</volume>: <fpage>2893</fpage>–<lpage>2917</lpage>.</citation>
</ref>
<ref id="bibr19-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geschickter</surname><given-names>C.</given-names></name>
<name><surname>Copeland</surname><given-names>M.</given-names></name>
</person-group> (<year>1928</year>) <article-title>Multiple myeloma</article-title>. <source>Arch Surg</source> <volume>16</volume>: <fpage>807</fpage>–<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr20-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grass</surname><given-names>S.</given-names></name>
<name><surname>Iida</surname><given-names>S.</given-names></name>
<name><surname>Wikowicz</surname><given-names>A.</given-names></name>
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Inagaki</surname><given-names>A.</given-names></name>
<name><surname>Shimizu</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma</article-title>. <source>Cancer Sci</source> <volume>102</volume>: <fpage>565</fpage>–<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr21-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grass</surname><given-names>S.</given-names></name>
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Ahlgrimm</surname><given-names>M.</given-names></name>
<name><surname>Fadle</surname><given-names>N.</given-names></name>
<name><surname>Regitz</surname><given-names>E.</given-names></name>
<name><surname>Pfoehler</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study</article-title>. <source>Lancet Oncol</source> <volume>10</volume>: <fpage>950</fpage>–<lpage>956</lpage>.</citation>
</ref>
<ref id="bibr22-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grass</surname><given-names>S.</given-names></name>
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Thome</surname><given-names>S.</given-names></name>
<name><surname>Weisenburger</surname><given-names>D.</given-names></name>
<name><surname>Witt</surname><given-names>V.</given-names></name>
<name><surname>Lynch</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011b</year>) <article-title>Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>635</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr23-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grass</surname><given-names>S.</given-names></name>
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Wikowicz</surname><given-names>A.</given-names></name>
<name><surname>Fadle</surname><given-names>N.</given-names></name>
<name><surname>Regitz</surname><given-names>E.</given-names></name>
<name><surname>Held</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011c</year>) <article-title>New Insights in the Pathogenesis of MGUS, multiple myeloma (MM) and Waldenström’s Mmcroglobulinemia (WM): chronic antigenic stimulation by autoantigenic targets of paraproteins is mediated by CD4+ t-cells</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>472</fpage>.</citation>
</ref>
<ref id="bibr24-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grass</surname><given-names>S.</given-names></name>
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Wikowicz</surname><given-names>A.</given-names></name>
<name><surname>Terpos</surname><given-names>E.</given-names></name>
<name><surname>Ziepert</surname><given-names>M.</given-names></name>
<name><surname>Nikolaus</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2011d</year>) <article-title>Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia</article-title>. <source>Blood</source> <volume>117</volume>: <fpage>2918</fpage>–<lpage>2923</lpage>.</citation>
</ref>
<ref id="bibr25-2040620713485375">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Gudmundsson</surname><given-names>J.</given-names></name>
<name><surname>Sulem</surname><given-names>P.</given-names></name>
<name><surname>Rafnar</surname><given-names>T.</given-names></name>
<name><surname>Bergthorsson</surname><given-names>J.</given-names></name>
<name><surname>Manolescu</surname><given-names>A.</given-names></name>
<name><surname>Gudbjartsson</surname><given-names>D.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer</article-title>. <conf-name>Nat Genet</conf-name> <volume>40</volume>: <fpage>281</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr26-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hall</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>M.</given-names></name>
<name><surname>Newman</surname><given-names>B.</given-names></name>
<name><surname>Morrow</surname><given-names>J.</given-names></name>
<name><surname>Anderson</surname><given-names>L.</given-names></name>
<name><surname>Huey</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>Linkage of early-onset familial breast cancer to chromosome 17q21</article-title>. <source>Science</source> <volume>250</volume>: <fpage>1684</fpage>–<lpage>1689</lpage>.</citation>
</ref>
<ref id="bibr27-2040620713485375">
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Howlader</surname><given-names>N.</given-names></name>
<name><surname>Noone</surname><given-names>A.</given-names></name>
<name><surname>Krapcho</surname><given-names>M.</given-names></name>
<name><surname>Neyman</surname><given-names>N.</given-names></name>
<name><surname>Aminou</surname><given-names>R.</given-names></name>
<name><surname>Altekruse</surname><given-names>S.</given-names></name><etal/>
</person-group>. (eds) (<year>2012</year>) <source>SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations).</source> <publisher-loc>Bethseda, MD</publisher-loc>: <publisher-name>National Cancer Institute</publisher-name>.</citation>
</ref>
<ref id="bibr28-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>A.</given-names></name>
<name><surname>Ho</surname><given-names>C.</given-names></name>
<name><surname>Ponzielli</surname><given-names>R.</given-names></name>
<name><surname>Barsyte-Lovejoy</surname><given-names>D.</given-names></name>
<name><surname>Bouffet</surname><given-names>E.</given-names></name>
<name><surname>Picard</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells</article-title>. <source>Cancer Res</source> <volume>65</volume>: <fpage>5607</fpage>–<lpage>5619</lpage>.</citation>
</ref>
<ref id="bibr29-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jain</surname><given-names>M.</given-names></name>
<name><surname>Ascensao</surname><given-names>J.</given-names></name>
<name><surname>Schechter</surname><given-names>G.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Familial myeloma and monoclonal gammopathy: a report of eight African American families</article-title>. <source>Am J Hematol</source> <volume>84</volume>: <fpage>34</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr30-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kiemeney</surname><given-names>L.</given-names></name>
<name><surname>Grotenhuis</surname><given-names>A.</given-names></name>
<name><surname>Vermeulen</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Genome-wide association studies in bladder cancer: first results and potential relevance</article-title>. <source>Curr Opin Urol</source> <volume>19</volume>: <fpage>540</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr31-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kristinsson</surname><given-names>S.</given-names></name>
<name><surname>Bjorkholm</surname><given-names>M.</given-names></name>
<name><surname>Goldin</surname><given-names>L.</given-names></name>
<name><surname>Blimark</surname><given-names>C.</given-names></name>
<name><surname>Mellqvist</surname><given-names>U.</given-names></name>
<name><surname>Wahlin</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden</article-title>. <source>Int J Cancer</source> <volume>125</volume>: <fpage>2147</fpage>–<lpage>2150</lpage>.</citation>
</ref>
<ref id="bibr32-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyle</surname><given-names>R.</given-names></name>
<name><surname>Rajkumar</surname><given-names>S.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Multiple myeloma</article-title>. <source>N Engl J Med</source> <volume>351</volume>: <fpage>1860</fpage>–<lpage>1873</lpage>.</citation>
</ref>
<ref id="bibr33-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kyle</surname><given-names>R.</given-names></name>
<name><surname>Therneau</surname><given-names>T.</given-names></name>
<name><surname>Rajkumar</surname><given-names>S.</given-names></name>
<name><surname>Larson</surname><given-names>D.</given-names></name>
<name><surname>Plevak</surname><given-names>M.</given-names></name>
<name><surname>Offord</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Prevalence of monoclonal gammopathy of undetermined significance</article-title>. <source>N Engl J Med</source> <volume>354</volume>: <fpage>1362</fpage>–<lpage>1369</lpage>.</citation>
</ref>
<ref id="bibr34-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leech</surname><given-names>S.</given-names></name>
<name><surname>Brian</surname><given-names>C.</given-names></name>
<name><surname>Elston</surname><given-names>R.</given-names></name>
<name><surname>Rainey</surname><given-names>J.</given-names></name>
<name><surname>Bickers</surname><given-names>J.</given-names></name>
<name><surname>Pelias</surname><given-names>M.</given-names></name>
</person-group> (<year>1983</year>) <article-title>Genetic studies in multiple Myeloma</article-title>. <source>Cancer</source> <volume>51</volume>: <fpage>1408</fpage>–<lpage>1411</lpage>.</citation>
</ref>
<ref id="bibr35-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindblom</surname><given-names>A.</given-names></name>
<name><surname>Tannergard</surname><given-names>P.</given-names></name>
<name><surname>Werelius</surname><given-names>B.</given-names></name>
<name><surname>Nordenskjold</surname><given-names>M.</given-names></name>
</person-group> (<year>1993</year>) <article-title>Genetic mapping of a second locus predisposing to hereditary non-polyposis colon cancer</article-title>. <source>Nat Genet</source> <volume>5</volume>: <fpage>279</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr36-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lynch</surname><given-names>H.</given-names></name>
<name><surname>Watson</surname><given-names>P.</given-names></name>
<name><surname>Tarantolo</surname><given-names>S.</given-names></name>
<name><surname>Wiernik</surname><given-names>P.</given-names></name>
<name><surname>Quinn-Laquer</surname><given-names>B.</given-names></name>
<name><surname>Isgur Bergsagel</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Phenotypic heterogeneity in multiple myeloma families</article-title>. <source>J Clin Oncol</source> <volume>23</volume>: <fpage>685</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr37-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maertens</surname><given-names>G.</given-names></name>
<name><surname>Cherepanov</surname><given-names>P.</given-names></name>
<name><surname>Engelman</surname><given-names>A.</given-names></name>
</person-group> (<year>2006</year>) <article-title>Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin</article-title>. <source>J Cell Sci</source> <volume>119</volume>: <fpage>2563</fpage>–<lpage>2571</lpage>.</citation>
</ref>
<ref id="bibr38-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mandema</surname><given-names>E.</given-names></name>
<name><surname>Wildervanck</surname><given-names>L.</given-names></name>
</person-group> (<year>1954</year>) <article-title>[Kahler’s disease (multiple myeloma) in two sisters]</article-title>. <source>J Genet Hum</source> <volume>3</volume>: <fpage>170</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr39-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martino</surname><given-names>A.</given-names></name>
<name><surname>Campa</surname><given-names>D.</given-names></name>
<name><surname>Jamroziak</surname><given-names>K.</given-names></name>
<name><surname>Reis</surname><given-names>R.</given-names></name>
<name><surname>Sainz</surname><given-names>J.</given-names></name>
<name><surname>Buda</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma</article-title>. <source>Br J Haematol</source> <volume>158</volume>: <fpage>805</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr40-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mason</surname><given-names>D.</given-names></name>
<name><surname>Cullen</surname><given-names>P.</given-names></name>
</person-group> (<year>1975</year>) <article-title>HL-A antigen frequencies in myeloma</article-title>. <source>Tissue Antigens</source> <volume>5</volume>: <fpage>238</fpage>–<lpage>245</lpage>.</citation>
</ref>
<ref id="bibr41-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKay</surname><given-names>J.</given-names></name>
<name><surname>Hung</surname><given-names>R.</given-names></name>
<name><surname>Gaborieau</surname><given-names>V.</given-names></name>
<name><surname>Boffetta</surname><given-names>P.</given-names></name>
<name><surname>Chabrier</surname><given-names>A.</given-names></name>
<name><surname>Byrnes</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Lung cancer susceptibility locus at 5p15.33</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>1404</fpage>–<lpage>1406</lpage>.</citation>
</ref>
<ref id="bibr42-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyerding</surname><given-names>H.</given-names></name>
</person-group> (<year>1925</year>) <article-title>Multiple myeloma</article-title>. <source>Radiology</source> <volume>5</volume>: <fpage>132</fpage>.</citation>
</ref>
<ref id="bibr43-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monckton</surname><given-names>D.</given-names></name>
<name><surname>Caskey</surname><given-names>C.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Unstable triplet repeat diseases</article-title>. <source>Circulation</source> <volume>91</volume>: <fpage>513</fpage>–<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr44-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morgan</surname><given-names>G.</given-names></name>
<name><surname>Johnsen</surname><given-names>H.</given-names></name>
<name><surname>Goldschmidt</surname><given-names>H.</given-names></name>
<name><surname>Palumbo</surname><given-names>A.</given-names></name>
<name><surname>Cavo</surname><given-names>M.</given-names></name>
<name><surname>Sonneveld</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Myeloma Genetics International Consortium</article-title>. <source>Leuk Lymphoma</source> <volume>53</volume>: <fpage>796</fpage>–<lpage>800</lpage>.</citation>
</ref>
<ref id="bibr45-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papaemmanuil</surname><given-names>E.</given-names></name>
<name><surname>Hosking</surname><given-names>F.</given-names></name>
<name><surname>Vijayakrishnan</surname><given-names>J.</given-names></name>
<name><surname>Price</surname><given-names>A.</given-names></name>
<name><surname>Olver</surname><given-names>B.</given-names></name>
<name><surname>Sheridan</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>1006</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr46-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parkin</surname><given-names>D.</given-names></name>
<name><surname>Bray</surname><given-names>F.</given-names></name>
<name><surname>Ferlay</surname><given-names>J.</given-names></name>
<name><surname>Pisani</surname><given-names>P.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Global cancer statistics, 2002</article-title>. <source>CA Cancer J Clin</source> <volume>55</volume>: <fpage>74</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr47-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>M.</given-names></name>
<name><surname>Wadee</surname><given-names>A.</given-names></name>
<name><surname>Galpin</surname><given-names>J.</given-names></name>
<name><surname>Gavalakis</surname><given-names>C.</given-names></name>
<name><surname>Fourie</surname><given-names>A.</given-names></name>
<name><surname>Kuschke</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>HLA class I and class II antigens associated with multiple myeloma in southern Africa</article-title>. <source>Clin Lab Haematol</source> <volume>24</volume>: <fpage>215</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr48-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peltomaki</surname><given-names>P.</given-names></name>
<name><surname>Aaltonen</surname><given-names>L.</given-names></name>
<name><surname>Sistonen</surname><given-names>P.</given-names></name>
<name><surname>Pylkkanen</surname><given-names>L.</given-names></name>
<name><surname>Mecklin</surname><given-names>J.</given-names></name>
<name><surname>Jarvinen</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Genetic mapping of a locus predisposing to human colorectal cancer</article-title>. <source>Science</source> <volume>260</volume>: <fpage>810</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr49-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pottern</surname><given-names>L.</given-names></name>
<name><surname>Gart</surname><given-names>J.</given-names></name>
<name><surname>Nam</surname><given-names>J.</given-names></name>
<name><surname>Dunston</surname><given-names>G.</given-names></name>
<name><surname>Wilson</surname><given-names>J.</given-names></name>
<name><surname>Greenberg</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>HLA and multiple myeloma among black and white men: evidence of a genetic association</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>1</volume>: <fpage>177</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr50-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Pfreundschuh</surname><given-names>M.</given-names></name>
<name><surname>Ahlgrimm</surname><given-names>M.</given-names></name>
<name><surname>Fadle</surname><given-names>N.</given-names></name>
<name><surname>Regitz</surname><given-names>E.</given-names></name>
<name><surname>Murawski</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS</article-title>. <source>Int J Cancer</source> <volume>125</volume>: <fpage>656</fpage>–<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr51-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preuss</surname><given-names>K.</given-names></name>
<name><surname>Pfreundschuh</surname><given-names>M.</given-names></name>
<name><surname>Fadle</surname><given-names>N.</given-names></name>
<name><surname>Regitz</surname><given-names>E.</given-names></name>
<name><surname>Raudies</surname><given-names>S.</given-names></name>
<name><surname>Murwaski</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Hyperphosphorylation of autoantigenic targets of paraproteins is due to inactivation of PP2A</article-title>. <source>Blood</source> <volume>118</volume>: <fpage>3340</fpage>–<lpage>3346</lpage>.</citation>
</ref>
<ref id="bibr52-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shete</surname><given-names>S.</given-names></name>
<name><surname>Hosking</surname><given-names>F.</given-names></name>
<name><surname>Robertson</surname><given-names>L.</given-names></name>
<name><surname>Dobbins</surname><given-names>S.</given-names></name>
<name><surname>Sanson</surname><given-names>M.</given-names></name>
<name><surname>Malmer</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Genome-wide association study identifies five susceptibility loci for glioma</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>899</fpage>–<lpage>904</lpage>.</citation>
</ref>
<ref id="bibr53-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sobol</surname><given-names>H.</given-names></name>
<name><surname>Vey</surname><given-names>N.</given-names></name>
<name><surname>Sauvan</surname><given-names>R.</given-names></name>
<name><surname>Philip</surname><given-names>N.</given-names></name>
<name><surname>Noguchi</surname><given-names>T.</given-names></name>
<name><surname>Eisinger</surname><given-names>F.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Re: familial multiple myeloma: a family study and review of the literature</article-title>. <source>J Natl Cancer Inst</source> <volume>94</volume>: <fpage>461</fpage>–<lpage>462</lpage>; author reply 463.</citation>
</ref>
<ref id="bibr54-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Struewing</surname><given-names>J.</given-names></name>
<name><surname>Hartge</surname><given-names>P.</given-names></name>
<name><surname>Wacholder</surname><given-names>S.</given-names></name>
<name><surname>Baker</surname><given-names>S.</given-names></name>
<name><surname>Berlin</surname><given-names>M.</given-names></name>
<name><surname>McAdams</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews</article-title>. <source>N Engl J Med</source> <volume>336</volume>: <fpage>1401</fpage>–<lpage>1408</lpage>.</citation>
</ref>
<ref id="bibr55-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trevino</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>W.</given-names></name>
<name><surname>French</surname><given-names>D.</given-names></name>
<name><surname>Hunger</surname><given-names>S.</given-names></name>
<name><surname>Carroll</surname><given-names>W.</given-names></name>
<name><surname>Devidas</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Germline genomic variants associated with childhood acute lymphoblastic leukemia</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>1001</fpage>–<lpage>1005</lpage>.</citation>
</ref>
<ref id="bibr56-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Broderick</surname><given-names>P.</given-names></name>
<name><surname>Webb</surname><given-names>E.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Vijayakrishnan</surname><given-names>J.</given-names></name>
<name><surname>Matakidou</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Common 5p15.33 and 6p21.33 variants influence lung cancer risk</article-title>. <source>Nat Genet</source> <volume>40</volume>: <fpage>1407</fpage>–<lpage>1409</lpage>.</citation>
</ref>
<ref id="bibr57-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wooster</surname><given-names>R.</given-names></name>
<name><surname>Neuhausen</surname><given-names>S.</given-names></name>
<name><surname>Mangion</surname><given-names>J.</given-names></name>
<name><surname>Quirk</surname><given-names>Y.</given-names></name>
<name><surname>Ford</surname><given-names>D.</given-names></name>
<name><surname>Collins</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13</article-title>. <source>Science</source> <volume>265</volume>: <fpage>2088</fpage>–<lpage>2090</lpage>.</citation>
</ref>
<ref id="bibr58-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wrensch</surname><given-names>M.</given-names></name>
<name><surname>Jenkins</surname><given-names>R.</given-names></name>
<name><surname>Chang</surname><given-names>J.</given-names></name>
<name><surname>Yeh</surname><given-names>R.</given-names></name>
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<name><surname>Decker</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>905</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr59-2040620713485375">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Ye</surname><given-names>Y.</given-names></name>
<name><surname>Kiemeney</surname><given-names>L.</given-names></name>
<name><surname>Sulem</surname><given-names>P.</given-names></name>
<name><surname>Rafnar</surname><given-names>T.</given-names></name>
<name><surname>Matullo</surname><given-names>G.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer</article-title>. <source>Nat Genet</source> <volume>41</volume>: <fpage>991</fpage>–<lpage>995</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>